Focus:
Uncategorized
-
29 June 2020
Covid-19 drug studies could highlight speed, flexibility and reduced risk of virtual clinical trials
The speed, flexibility and strong risk-benefit ratio of virtual clinical trials could all be highlighted in the assessment of potential Covid-19 treatments, according to industry bosses. Dr Calvin H Knowlton,...
-
26 June 2020
Gilead’s remdesivir to commence Phase I trials as inhaled therapy to target mild Covid-19 patients
Earlier this month, Gilead announced that it will commence Phase I clinical trials for inhaled remdesivir in healthy volunteers, with the aim to extend further studies in patients with Covid-19...
-
25 June 2020
Dexamethasone, an unexpected drug, shows promise in treating Covid-19
At present, there are more than 2,200 clinical trials attempting to find a Covid-19 vaccine or therapy. The National Institute of Health recently stopped its hydroxychloroquine clinical trial, concluding that...
-
23 June 2020
CanSino’s, J&J’s Covid-19 vaccines may be stifled by pre-existing antibodies while AstraZeneca’s, ReiThera’s may need booster
Notwithstanding its benefits over other vaccine technologies for Covid-19, adenovirus vector vaccines could be tripped up by pre-existing antibodies to the vectors used and the requirement for a second injection...
-
19 June 2020
A closer look at Regeneron and its efforts to provide the world with a Covid-19 treatment
Like many firms in the pharmaceutical sector, Regeneron has turned a great deal of attention towards the fight against Covid-19 in recent weeks and months. Having already entered one of...
-
18 June 2020
The UK leads Covid-19 clinical investigations in Europe
As Europe has been significantly impacted by the Covid-19 pandemic, a huge amount of clinical research is focused on identifying effective therapies and vaccines. GlobalData analysed the Covid-19 clinical trials...
-
18 June 2020
Myovant’s Phase III relugolix trial’s cardiovascular event reduction trend inconclusive
At the beginning of the month, Myovant’s share price skyrocketed 55% after data from its Phase III HERO trial (NCT03085095) comparing relugolix with generic leuprolide were presented at the recent...
-
18 June 2020
AstraZeneca’s Tagrisso divides on immediate adoption in adjuvant non-small cell lung cancer
AstraZeneca’s Tagrisso (osimertinib) may not find widespread adoption in the adjuvant setting for non-small cell lung cancer (NSCLC), regardless of positive Phase III data, in the absence of a consensus...
-
15 June 2020
Long-term efficacy data shows MDMA is effective for treating PTSD
The Multidisciplinary Association for Psychedelic Studies (MAPS) is producing the first-in-class innovator drug midomafetamine (MDMA) as therapy for chronic and delayed-onset post-traumatic stress disorder (PTSD), currently in Phase III development...
-
15 June 2020
FibroGen: The company attempting to treat pneumonia in Covid-19 patients
In its attempt to provide treatments for Covid-19 patients, American biopharma firm FibroGen has chosen to tackle the infection slightly differently to many of its peers in the industry. Antivirals...